Shire’s potential blockbuster Xiidra (lifitegrast) has been approved in the US for dry eye disease, bouncing back from a rejection by the regulator late last year. Xiidra, in a 5% solution ...

Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with Shire in 2019, outlining the sales potential in this market niche. But with ...

The dry eye portfolio is nearing $1 billion in annual revenue, driven by the success of Miebo and Xiidra, which benefited from direct-to-consumer campaigns. CFO Sam Eldessouky reported total ...